WallStSmart

Notable Labs Inc. (NTBL)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BeiGene, Ltd. generates 1958035% more annual revenue ($6.13B vs $313,000). ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).

NTBL

Avoid

27

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: -5.53

ONC

Buy

64

out of 100

Grade: C+

Growth: 9.3Profit: 6.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NTBL.

ONCUndervalued (+80.1%)

Margin of Safety

+80.1%

Fair Value

$1767.21

Current Price

$348.08

$1419.13 discount

UndervaluedFair: $1767.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NTBL2 strengths · Avg: 9.5/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

ONC4 strengths · Avg: 8.8/10
EPS GrowthGrowth
166.7%10/10

Earnings expanding 166.7% YoY

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.778/10

Growing faster than its price suggests

Revenue GrowthGrowth
29.6%8/10

Revenue surging 29.6% year-over-year

Areas to Watch

NTBL4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.39M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
64.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : NTBL

The strongest argument for NTBL centers on Price/Book, Debt/Equity.

Bull Case : ONC

The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bear Case : NTBL

The primary concerns for NTBL are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.

Key Dynamics to Monitor

NTBL profiles as a value stock while ONC is a growth play — different risk/reward profiles.

ONC is growing revenue faster at 29.6% — sustainability is the question.

ONC generates stronger free cash flow (596M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ONC scores higher overall (64/100 vs 27/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Notable Labs Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Notable Labs, Inc. is a clinical-stage platform therapeutic company that develops predictive precision medicine for cancer patients. The company is headquartered in Foster City, California.

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?